Zevra Therapeutics, Inc. - ZVRA
About Gravity Analytica
Recent News
- 10.06.2025 - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 10.06.2025 - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 09.18.2025 - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyr
- 09.18.2025 - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyr
- 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
- 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
- 09.04.2025 - Efficacy results across a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treatment of Niemann-Pick disease type C in patients treated with miglustat
- 09.04.2025 - Arimoclomol for the treatment of Niemann-Pick disease type C in a real-world setting: long-term outcomes from an expanded access program in the United States
- 09.04.2025 - Arimoclomol upregulates expression of genes belonging to the coordinated lysosomal expression and regulation (CLEAR) network
- 09.04.2025 - Safety and efficacy of arimoclomol in a pediatric substudy of Niemann-Pick disease type C patients aged 6 to